Overview

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female

Status:
Completed

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to investigate bioequivalence of a newly developed fixed dose combination (FDC) tablet containing empagliflozin and metformin extended release compared to the free combination of empagliflozin and metformin extended release under fed conditions.

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Collaborator:

Eli Lilly and Company

Treatments:

Empagliflozin
Metformin